Cladribine
Pediatric AML
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
51 Active assets in the Pediatric AML cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Joanna Yi | Phase 3 | BBB |
Cytosin-Arabinosid Children's Oncology Group | Phase 3 | BBB |
METHOTREXATE Children's Oncology Group | Phase 3 | BBB |
FILGRASTIM National Cancer Institute (NCI) | Phase 3 | BBB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Cladribine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →